Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 94

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 94
---
                                                          
 per annum for the ten 10                                                                                                               
 month term of the Note for an aggregate Guaranteed Interest                                                                            
 $25,000. The Principal Amount and the Guaranteed Interest shall be due and payable in ten equal monthly payments $27,500 commencing    
 on November 4, 2024, and continuing on the fourth day of each month thereafter (each, a “Monthly Payment Date”) until                  
 paid in full not later than September 4, 2025.                                                                                         |
| vii. | On                                                                                                                                     
 October 28, 2024 a promissory note in the amount $48,500 (“Note”) was reclassified as a convertible note payable due                   
 to a negotiated change in the terms and conditions of the Note. The Note may be converted into the Common Shares of Regen at a price   
 per share (“Conversion Price”) equivalent to the lower of (a) a 50% discount to the lowest closing bid price of the common             
 stock of the Company during the ten reading day period immediately prior to the date a conversion notice is given by the Lender to     
 Regen or (b) $0.04 per common share. As of March 31, 2025 $28,500 of the principal balance of the Note remained outstanding.           |

8. DERIVATIVE LIABILITY

The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $1,691,143 was recognized by the Company as of March 31, 2025.

| 78 |

Derivative Liability consisted of the following :

<div align='center'>SCHEDULE OF DERIVATIVE LIABILITY</div>

|                      |     | As of | March 31, 
      2025 |     | As of | September 30,